| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/22/2007 | US20070066527 Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
| 03/22/2007 | US20070066526 Method for reducing risk of and extent of injury due to stroke in hypertensive subjects |
| 03/22/2007 | US20070066525 Compositions and therapeutic methods using morphogenic proteins |
| 03/22/2007 | US20070066524 for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 03/22/2007 | US20070066523 Chemokine analogs for the treatment of human diseases |
| 03/22/2007 | US20070066522 Tumor inhibition by modulating sprouty expression or activity |
| 03/22/2007 | US20070066521 Short RNA-binding proteins |
| 03/22/2007 | US20070066520 Novel epidermal growth factor protein and gene, and methods of use therefor |
| 03/22/2007 | US20070066519 Use of human growth hormone in multiple system atrophy |
| 03/22/2007 | US20070066518 Pharmaceutical composition for inducing apoptosis comprising a fusion protein between bfl-1 and green fluorescent protein or a gene encoding same |
| 03/22/2007 | US20070066517 Composition and method for treating graft-versus-host disease |
| 03/22/2007 | US20070066516 Compounds comprising cyclized somatostatin receptor binding peptides |
| 03/22/2007 | US20070066515 Novel glycoprotein and pharmaceutical composition containing the same |
| 03/22/2007 | US20070066514 Regulation of mineral and skeletal metabolism |
| 03/22/2007 | US20070066513 photosensitizers used in the photodynamic therapy of microbial infections, tumors, pre-cancerous and proliferative pathologies and/or in the diagnosis, as well as for blood and blood derivatives sterilization |
| 03/22/2007 | US20070066512 Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| 03/22/2007 | US20070065938 Perivascular mesenchymal precursor cells |
| 03/22/2007 | US20070065917 Endogenous and non-endogenous, constitutively activated human G protein-coupled receptions |
| 03/22/2007 | US20070065915 Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals |
| 03/22/2007 | US20070065908 antiinflammatories, antiviral agents; coadministering with antibiotic; surface decontamination |
| 03/22/2007 | US20070065887 Diagnosis of pre-cancerous conditions using pcdgf agents |
| 03/22/2007 | US20070065885 Methods for shp1 mediated neuroprotection |
| 03/22/2007 | US20070065882 Acetylcholinesterase-derived peptides and uses thereof |
| 03/22/2007 | US20070065875 NTB-A, a surface molecule involved in natural killer cells activity |
| 03/22/2007 | US20070065868 IL-17 receptor like molecules and uses thereof |
| 03/22/2007 | US20070065849 Nucleic acid encoding eosinophil eotaxin receptor |
| 03/22/2007 | US20070065848 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor |
| 03/22/2007 | US20070065820 Lipid-associated molecules |
| 03/22/2007 | US20070065819 Novel fprl1 ligands and use thereof |
| 03/22/2007 | US20070065810 Diagnosis and treatment of cervical cancer |
| 03/22/2007 | US20070065804 Method for PR-39 peptide mediated selective inhibition of IkappaBalpha degradation |
| 03/22/2007 | US20070065527 Activated citrus peel extract |
| 03/22/2007 | US20070065521 Composition and method for treating iron deficiency anemia |
| 03/22/2007 | US20070065514 tumor necrosis factor alpha (TNF alpha ) mutein attached to substrates, to create an adsorbent matrix, that permit binding of immune system inhibitors such as soluble TNF receptors, thereby inducing a vigorous immune response while minimizing toxicity |
| 03/22/2007 | US20070065506 Keratin and soluble derivatives thereof for a nutraceutical and to reduce oxidative stress and to reduce inflammation and to promote skin health |
| 03/22/2007 | US20070065505 Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form |
| 03/22/2007 | US20070065498 Encapsulated arsenic drugs |
| 03/22/2007 | US20070065497 Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy |
| 03/22/2007 | US20070065469 Liquid formulations with high concentration of human growth hormone (high) comprising glycine |
| 03/22/2007 | US20070065465 Conjugate vaccines for the prevention of dental caries |
| 03/22/2007 | US20070065458 Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural motifs |
| 03/22/2007 | US20070065456 Nutritional supplements |
| 03/22/2007 | US20070065455 relates to osteopontin (Eta-1) polypeptides ; for enhancing an immune response in an animal; for therapy and prophylaxis of infectious diseases or cancer; immunization |
| 03/22/2007 | US20070065454 Liposomal vaccine |
| 03/22/2007 | US20070065451 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 03/22/2007 | US20070065450 Transcription factor as repressor of expression of E-cadherin; drug screening |
| 03/22/2007 | US20070065445 Novel cyclooxygenase variants and methods of use |
| 03/22/2007 | US20070065443 Fructoseamine 3 kinase and the formation of collagen and elastin |
| 03/22/2007 | US20070065442 Compositions and methods for treating hyperimmune response in the eye |
| 03/22/2007 | US20070065441 Human PF4A receptors, nucleic acid encoding and antibodies binding thereto |
| 03/22/2007 | US20070065435 Gamma-1 And Gamma-3 Anti-Human CD23 Monoclonal Antibodies And Use Thereof As Therapeutics |
| 03/22/2007 | US20070065434 Gamma-1 And Gamma-3 Anti-Human CD23 Monoclonal Antibodies And Use Thereof As Therapeutics |
| 03/22/2007 | US20070065433 Methods and compositions for the treatment of meconium aspiration syndrome |
| 03/22/2007 | US20070065431 A polynucleotide encoding a monomeric non-antibody ligand having a loop partly modified or replaced by or amino acid(s); improved solubility; medical diagnosis; targets of drugs, steroids, pesticides, antigens, growth factors, tumour markers, cell surface proteins or viral coat proteins |
| 03/22/2007 | US20070065429 Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques |
| 03/22/2007 | US20070065427 Agents that modulate immune cell activation and methods of use thereof |
| 03/22/2007 | US20070065426 Tumor necrosis factor binding ligands |
| 03/22/2007 | US20070065424 Rationally designed polysaccharide lyases derived from chondroitinase B |
| 03/22/2007 | US20070065421 Inducing expression of puma to reduce joint inflammation in the treatment of arthritis |
| 03/22/2007 | US20070065414 Enhanced delivery of cells |
| 03/22/2007 | US20070065410 E4 or F4 and Bcl-2 peptides of small dimension (less than 30 amino acids) that bind a PP2A holoenzyme or one of its sub-units, particularly useful as anticancer, antiviral and antiparasitic agents |
| 03/22/2007 | US20070065408 Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b |
| 03/22/2007 | US20070065407 Interferon-Alpha Polypeptides and Conjugates |
| 03/22/2007 | US20070065406 Homogeneous preparations of IL-28 and IL-29 |
| 03/22/2007 | US20070065405 Uses of human Zven proteins and polynucleotides |
| 03/22/2007 | US20070065404 Uses of humans zven proteins and polynucleotides |
| 03/22/2007 | US20070065403 Uses of human Zven proteins and polynucleotides |
| 03/22/2007 | US20070065402 Methods for treating viral infection using il-28 and il-29 |
| 03/22/2007 | US20070065401 Methods for treating viral infection using il-28 and il-29 |
| 03/22/2007 | US20070065400 Treatment of tumor metastases and cancer |
| 03/22/2007 | US20070065399 Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules |
| 03/22/2007 | US20070065398 Photoactivatable composition and uses thereof |
| 03/22/2007 | US20070065371 Novel Dry Powder Inhalation System For Transpulmonary Administration |
| 03/22/2007 | US20070065368 Compositions and Methods for Suppressing Fibrocytes and for Detecting Fibrocyte Differentiation |
| 03/22/2007 | US20070065367 Method of treating pulmonary disease with interferons |
| 03/22/2007 | US20070065362 Gastrin receptor-avid peptide conjugates |
| 03/22/2007 | DE102005044102A1 Composition for treating malignant myeloma or other CD138-positive tumors, comprises a ULBP2-antiCD138 protein for stimulating an immune response through the NKG2D receptor |
| 03/22/2007 | CA2818900A1 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| 03/22/2007 | CA2621939A1 Therapeutic use of outer shigella protein f (os pf) |
| 03/22/2007 | CA2621641A1 Ph sensitive nanoparticle formulation for oral delivery of proteins/peptides |
| 03/22/2007 | CA2621549A1 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor xa |
| 03/22/2007 | CA2621363A1 Methods and compositions for modulating tumor cell activity |
| 03/21/2007 | EP1764616A2 Method for identifying apoptosis modified proteins |
| 03/21/2007 | EP1764413A1 Protein preparation containing s1-5 |
| 03/21/2007 | EP1764372A1 Tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors for treatment of cancer |
| 03/21/2007 | EP1764371A1 Agonist antibodies that bind to the LT-beta receptor, thereby modulating adiposity-associated phenotypes, and their use in therapy |
| 03/21/2007 | EP1764370A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2 |
| 03/21/2007 | EP1764113A1 Antibodies against lung cancer, antigens and methods of use thereof for treating lung cancer |
| 03/21/2007 | EP1764106A2 Use of insulin-like growth factor I for the inhibition of ischemic injury involving the liver |
| 03/21/2007 | EP1763366A1 Treatment of cancer |
| 03/21/2007 | EP1763363A1 Diaminooxidase-containing pharmaceutical compositions |
| 03/21/2007 | EP1763362A1 Use of morphogenic proteins for treating cartilage defects |
| 03/21/2007 | EP1763361A2 Steroid sparing agents and their use |
| 03/21/2007 | EP1696945A4 Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| 03/21/2007 | EP1675608B1 Injectable calcium phosphate solid rods for delivery of osteogenic proteins |
| 03/21/2007 | EP1572884A4 Dominant negative variants of methionine aminopeptidase 2 (metap2) and clinical uses thereof |
| 03/21/2007 | EP1479396B1 Agent for controlling circadian rhythm disorder |
| 03/21/2007 | EP1470221B1 Ralstonia ahl-acylase gene |
| 03/21/2007 | EP1399113B1 Cosmetic or dermatological composition comprising n-acylaminoamide derivatives |
| 03/21/2007 | EP1397492B1 Modified and stabilized gdf propeptides and uses thereof |